oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
IBD Pharmacogenet, Royal Devon & Exeter Hosp, Exeter, England; Precis Med, Univ Exeter, Exeter, England.
Precision medicine, Exeter Medical School, University of Exeter, Exeter, England.
IBD Pharmacogenet, Royal Devon & Exeter Hosp, Exeter, England; Precision Med Exeter, Univ Exeter, Exeter, England.
IBD Pharmacogenet, Royal Devon & Exeter Hosp, Exeter, England.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Nature Genetics, ISSN 1061-4036, E-ISSN 1546-1718, Vol. 46, nr 10, s. 1131-1134Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Pancreatitis occurs in approximately 4% of patients treated with the thiopurines azathioprine or mercaptopurine. Its development is unpredictable and almost always leads to drug withdrawal. We identified patients with inflammatory bowel disease (IBD) who had developed pancreatitis within 3 months of starting these drugs from 168 sites around the world. After detailed case adjudication, we performed a genome-wide association study on 172 cases and 2,035 controls with IBD. We identified strong evidence of association within the class II HLA region, with the most significant association identified at rs2647087 (odds ratio 2.59, 95% confidence interval 2.07-3.26, P = 2 x 10(-16)). We replicated these findings in an independent set of 78 cases and 472 controls with IBD matched for drug exposure. Fine mapping of the H LA region identified association with the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype. Patients heterozygous at rs2647087 have a 9% risk of developing pancreatitis after administration of a thiopurine, whereas homozygotes have a 17% risk.

sted, utgiver, år, opplag, sider
Nature Publishing Group, 2014. Vol. 46, nr 10, s. 1131-1134
HSV kategori
Forskningsprogram
Genetik
Identifikatorer
URN: urn:nbn:se:oru:diva-38045DOI: 10.1038/ng.3093ISI: 000342554100018PubMedID: 25217962Scopus ID: 2-s2.0-84922070460OAI: oai:DiVA.org:oru-38045DiVA, id: diva2:758500
Merknad

Funding Agencies:

International Serious Adverse Events Consortium (iSAEC)

Crohn's and Colitis UK

Wellcome Trust Institutional Strategic Support Award 

Tilgjengelig fra: 2014-10-27 Laget: 2014-10-24 Sist oppdatert: 2018-09-06bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Halfvarson, Jonas

Søk i DiVA

Av forfatter/redaktør
Halfvarson, Jonas
Av organisasjonen
I samme tidsskrift
Nature Genetics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 507 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf